22.418 articles found

Improvement in Parkinson's disease patients achieved by coordination dynamics therapy.

Schalow G, Pääsuke M, Ereline J, Gapeyeva H.

Electromyogr Clin Neurophysiol · 2004-03-01

PMID: 15061399

The effect of physical therapy on balance of patients with Parkinson's disease.

Stankovic I.

Int J Rehabil Res · 2004-03-01

DOI: 10.1097/00004356-200403000-00007PMID: 15097170

Olanzapine as a possible treatment for anxiety due to vascular dementia: an open study.

Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A.

Am J Alzheimers Dis Other Demen · 2004-03-01

DOI: 10.1177/153331750401900215PMID: 15106388

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H.

Clin Neuropharmacol · 2004-03-01

DOI: 10.1097/00002826-200403000-00003PMID: 15252265

Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease.

Voon V, Lang AE.

Clin Neuropharmacol · 2004-03-01

DOI: 10.1097/00002826-200403000-00009PMID: 15252271

Adverse effects of risperidone and haloperidol treatment in schizophrenia.

Yen YC, Lung FW, Chong MY.

Prog Neuropsychopharmacol Biol Psychiatry · 2004-03-01

DOI: 10.1016/j.pnpbp.2003.10.006PMID: 14751424

Effect of levodopa treatment for parkinsonism in welders: A double-blind study.

Koller WC, Lyons KE, Truly W.

Neurology · 2004-03-01

DOI: 10.1212/01.wnl.0000113726.34734.15PMID: 15007122

[Neurosurgical treatment of Parkinson's disease].

Steude U.

MMW Fortschr Med · 2004-03-01

PMID: 15347074

Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

BENAVIDES JESUS, BOCCIO DANIEL, HENIN YVETTE, PIOT-GROSJEAN ODILE.

· 2004-02-25

Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

BENAVIDES JESUS, BOCCIO DANIEL, HENIN YVETTE, PIOT-GROSJEAN ODILE.

· 2004-02-25

Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

BENAVIDES JESUS, BOCCIO DANIEL, HENIN YVETTE, PIOT-GROSJEAN ODILE, HENIN.

· 2004-02-25

Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

BENAVIDES JESUS, BOCCIO DANIEL, HENIN YVETTE, PIOT-GROSJEAN ODILE, HENIN.

· 2004-02-25